Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Drug Manufacturers - Specialty & Generic

Healthcare
$1.50 +1047.56%

+$7.31 today

Market cap
$71.09M
Beta
-2.17
P/E (TTM)
-36.3
EPS (TTM)
-$1.50
52W Low $0.62High $13.08

Volume 0.02M

Average 0.10M

ZYBT EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA of -CN¥27.41M in Q4 FY2025

Q4 FY2025 EBITDA was -CN¥27.41M.

Context

  • EBITDA amounted to 36.5% of revenue in FY2025, up 13.7 pp from a year earlier.
  • EBITDA increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-CN¥27.41M-95.8% QoQ
Last fiscal yearDec 2025
-CN¥42.52M-199.8% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-199.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

EBITDA history

CNY · from the income statement

Latest · FY2025
(42.52M) CNY
Year-over-year change
-199.8%

EBITDA vs competitors

How ZYBT compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -199.8% is the 8th highest of 9, against a peer median of -6.7%.
  • EBITDA amounts to 36.5% of revenue for ZYBT, versus a peer median of 2296.7%.
ZYBT Competitors
EBITDA for ZYBT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PDEXPro-Dex, Inc.LTM Mar 2026$19.63M USD+41.4%+27.1%26.3%
APYXApyx Medical CorporationLTM Mar 2026-$2.44M USD+81.8%—4.4%
EXOZeXoZymes, Inc.LTM Mar 2026-$9.84M USD-54.8%——
SERASera Prognostics, Inc.LTM Mar 2026-$31.22M USD+2.8%—54764.9%
ONCYOncolytics Biotech Inc.LTM Mar 2026-CA$36.08M CAD-19.5%——
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$36.27M CAD-16.2%——
TILInstil Bio, Inc.LTM Mar 2026-$41.59M USD+38.3%——
ZYBTZhengye Biotechnology Holding LimitedFY2025-CN¥42.52M CNY-199.8%—36.5%
SRZNSurrozen, Inc.LTM Mar 2026-$342.25M USD-325.9%—4567.0%
Peer median (excluding ZYBT) —-6.7%+27.1%2296.7%

Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CNY
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue214.07M260.27M211.65M186.36M116.36M
Cost of Revenue88.67M106.75M81.8M95.06M92.49M
Gross Profit125.39M153.52M129.86M91.3M23.87M
Gross Margin58.6%59.0%61.4%49.0%20.5%
Research & Development11.37M13.42M11.9M12.79M18.01M
Selling, General & Admin58.19M63.56M66.63M63.84M74.92M
Operating Expenses73.01M87.69M84.87M74.86M92.12M
Depreciation & Amortization16.01M18.8M23.91M24.16M25.96M
EBITDA70.12M85.55M72.1M42.6M(42.52M)
EBITDA Margin32.8%32.9%34.1%22.9%-36.5%
Operating Income52.38M65.83M44.99M16.44M(68.25M)
Operating Margin24.5%25.3%21.3%8.8%-58.7%
Interest Income112K114K312K231K96K
Interest Expense1.05M2.84M4.42M4.04M3.4M
Other Income / Expenses683K(1.92M)(1.22M)(2.05M)(3.62M)
Income Before Tax53.07M63.91M43.76M14.39M(71.87M)
Pre-Tax Margin24.8%24.6%20.7%7.7%-61.8%
Income Tax Expense6.6M8.17M6.25M924K11.1M
Net Income38.96M46.74M31.46M11.31M(69.78M)
Net Margin18.2%18.0%14.9%6.1%-60.0%
EPS (Basic)0.851.020.690.24(1.40)
EPS (Diluted)0.830.990.670.24(1.40)
Weighted Avg Shares45.67M45.67M45.67M47.17M47.35M
Weighted Avg Shares (Diluted)47.17M47.17M47.17M47.17M47.35M

Zhengye Biotechnology Holding Limited

NASDAQ:ZYBT

Intrinsic Alpha fair value

Locked

Current Price

$1.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.